Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.35 |
| ▸ | CES2 | O00748 | 4/20 | 0.35 |
| ▸ | CES1 | P23141 | 4/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4952250 | 0.92 | — | — | |
| SCHEMBL5378688 | 0.87 | — | — | |
| SCHEMBL12967670 | 0.87 | — | — | |
| SCHEMBL15910005 | 0.84 | TSHR (0.71) | LMNATSHRNFKB1PMP22SLC22A6 | |
| SCHEMBL16257925 | 0.84 | — | — | |
| SCHEMBL14839286 | 0.84 | TSHR (0.52) | LMNATSHRNFKB1PMP22ALDH1A1 | |
| SCHEMBL14369099 | 0.84 | — | — | |
| SCHEMBL13707321 | 0.84 | — | — | |
| SCHEMBL4952228 | 0.82 | — | — | |
| SCHEMBL12967375 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016081670-A2 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-05-26 | — | — | WO | disclosed |
| US-20080146768-A1 | PROCESSES FOR PREPARING POLYMERS USING ALPHA,OMEGA-DIFUNCTIONAL ALDARAMIDES | E. I. DU PONT DE NEMOURS AND COMPANY | 2008-06-19 | — | — | US | disclosed |
| EP-1858955-A1 | PROCESSES USING ALPHA, OMEGA-DIFUNCTIONAL ALDARAMIDES AS MONOMERS AND CROSSLINKERS | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2007-11-28 | — | — | EP | disclosed |
| US-20060264672-A1 | Processes using alpha, omega-difunctional aldaramides as monomers and crosslinkers | E. I. DU PONT DE NEMOURS AND COMPANY | 2006-11-23 | — | — | US | disclosed |
| WO-2006091901-A1 | PROCESSES USING ALPHA, OMEGA-DIFUNCTIONAL ALDARAMIDES AS MONOMERS AND CROSSLINKERS | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2006-08-31 | — | — | WO | disclosed |
| US-6730810-B2 | HOMOGENOUS MIXTURE COMPRISING ACID HALIDE WITH HYDROXY CARBOXYLIC ACIDS AND ANHYDRIDE; DISCOLORATION INHIBITION | HUNTSMAN PETROCHEMICAL CORPORATION | 2004-05-04 | — | — | US | disclosed |
| US-20030120089-A1 | Anhydride stabilization | HUNTSMAN PETROCHEMICAL CORPORATION | 2003-06-26 | — | — | US | disclosed |
| EP-0303382-B1 | PROCESS FOR THE PREPARATION OF MESO 2,5-DIHALOADIPATES | PFIZER INC. (US) | 1992-03-18 | — | — | EP | disclosed |
| EP-0303382-A1 | Process for the preparation of meso 2,5-dihaloadipates | PFIZER INC. (US) | 1989-02-15 | — | — | EP | disclosed |
| US-4736059-A | Process for the preparation of meso 2,5-dihaloadipates | PFIZER INC. (US) | 1988-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030120089-A1 | Anhydride stabilization | CA7, CA4, CA9 | LMNA 1908/4885TSHR 4211/4885NFKB1 1878/4885 |
| US-20060264672-A1 | Processes using alpha, omega-difunctional aldaramides as monomers and crosslinkers | ALOX5, GSTO1, FASN | LMNA 1016/4885TSHR 4512/4885NFKB1 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.